A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies.

Trial Profile

A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2012

At a glance

  • Drugs Bortezomib; Docetaxel
  • Indications Advanced breast cancer; Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 17 May 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 17 May 2012 Actual patient number is 107 according to ClinicalTrials.gov.
    • 17 May 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top